mTORC 1 and mTORC 2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells

Increased mast cell burden is observed in the inflamed tissues and affected organs and tissues of patients with mast cell proliferative disorders. However, normal mast cells participate in host defense, so approaches to preferentially target clonally expanding mast cells are needed. We found that mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) are up-regulated in neoplastic and developing immature mast cells compared with their terminally differentiated counterparts. Elevated mTOR mRNA was also observed in bone marrow mononuclear cells of patients exhibiting mast-cell hyperplasia. Selective inhibition of mTORC1 and mTORC2 through genetic and pharmacologic manipulation revealed that, whereas mTORC1 may contribute to mast-cell survival, mTORC2 was only critical for homeostasis of neoplastic and dividing immature mast cells. The cytostatic effect of mTORC2 down-regulation in proliferating mast cells was determined to be via inhibition of cell-cycle progression. Because mTORC2 was observed to play little role in the homeostasis of differentiated, nonproliferating, mature mast cells, these data provide a rationale for adopting a targeted approaching selectively inhibiting mTORC2 to effectively reduce the proliferation of mast cells associated with inflammation and disorders of mast cell proliferation while leaving normal differentiated mast cells largely unaffected. (Blood. 2011;118(26):6803-6813)

[1]  Mi‐Sun Kim,et al.  Activation and Function of the mTORC1 Pathway in Mast Cells1 , 2008, The Journal of Immunology.

[2]  Mi‐Sun Kim,et al.  Glycogen Synthase Kinase 3β Activation Is a Prerequisite Signal for Cytokine Production and Chemotaxis in Human Mast Cells , 2009, The Journal of Immunology.

[3]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[4]  J. Woo,et al.  Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. , 2006, Developmental cell.

[5]  H. Schwalbe,et al.  Translation on demand by a simple RNA-based thermosensor , 2010, Nucleic acids research.

[6]  Kathryn G. Foster,et al.  Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony* , 2010, The Journal of Biological Chemistry.

[7]  R. Abraham,et al.  Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. , 2009, Seminars in oncology.

[8]  D. Smrz,et al.  Non-apoptotic Phosphatidylserine Externalization Induced by Engagement of Glycosylphosphatidylinositol-anchored Proteins* , 2007, Journal of Biological Chemistry.

[9]  E. Lalli,et al.  Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. , 2010, Cancer research.

[10]  K. Inoki,et al.  Signaling by Target of Rapamycin Proteins in Cell Growth Control , 2005, Microbiology and Molecular Biology Reviews.

[11]  M. Tsai,et al.  Mast cells in the promotion and limitation of chronic inflammation , 2007, Immunological reviews.

[12]  G. Nilsson,et al.  Phenotypic Characterization of the Human Mast‐Cell Line HMC‐1 , 1994, Scandinavian journal of immunology.

[13]  Foad Katirai,et al.  Mast cell: insight into remodeling a tumor microenvironment , 2011, Cancer and Metastasis Reviews.

[14]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[15]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Philippe P Roux,et al.  mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling , 2009, Molecular and Cellular Biology.

[17]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[18]  Mi‐Sun Kim,et al.  Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release. , 2008, Cellular signalling.

[19]  J. Marshall.  Mast-cell responses to pathogens , 2004, Nature Reviews Immunology.

[20]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[21]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[22]  M. Fay,et al.  KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. , 2007, The Journal of allergy and clinical immunology.

[23]  D. Metcalfe,et al.  Induction of Telomerase Activity During Development of Human Mast Cells from Peripheral Blood CD34+ Cells: Comparisons with Tumor Mast-Cell Lines1 , 2001, The Journal of Immunology.

[24]  L. Scott,et al.  Human Mast Cells Arise From a Progenitor Cell Population That Is CD 34 1 , c-kit , 1999 .

[25]  Shoko Iwaki,et al.  TLR‐mediated signaling pathways circumvent the requirement for DAP12 in mast cells for the induction of inflammatory mediator release , 2010, European journal of immunology.

[26]  K. Khazaie,et al.  Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. , 2009, Biochimica et biophysica acta.

[27]  E. Vellenga,et al.  Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells , 2009, European journal of haematology.

[28]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[29]  Joseph Gera,et al.  mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. , 2007, Cancer research.

[30]  Taous Khan,et al.  MicroRNAs: synthesis, mechanism, function, and recent clinical trials. , 2010, Biochimica et biophysica acta.

[31]  Andreas Beyer,et al.  Post-transcriptional Expression Regulation in the Yeast Saccharomyces cerevisiae on a Genomic Scale*S , 2004, Molecular & Cellular Proteomics.

[32]  J. Kinet,et al.  New developments in FcεRI regulation, function and inhibition , 2007, Nature Reviews Immunology.

[33]  S. Cohen,et al.  TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells , 2008, BMC Cancer.

[34]  M. Tsai,et al.  Mast cells in allergy and infection: Versatile effector and regulatory cells in innate and adaptive immunity , 2010, European journal of immunology.

[35]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[36]  C. Parent,et al.  Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. , 2011, Blood.

[37]  S. Schreiber,et al.  FKBP12-Rapamycin-associated Protein (FRAP) Autophosphorylates at Serine 2481 under Translationally Repressive Conditions* , 2000, The Journal of Biological Chemistry.

[38]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[39]  C. Bodemer,et al.  Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. , 2006, Blood.

[40]  K. Pan,et al.  Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. , 2011, Surgery.

[41]  N. Demartines,et al.  Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo , 2010, Molecular Cancer.

[42]  D. Metcalfe,et al.  Mast cells. , 1997, Physiological reviews.

[43]  D. Metcalfe,et al.  Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. , 2003, Leukemia research.